<?xml version='1.0' encoding='utf-8'?>
<document id="32200996"><sentence text="[PET imaging to study the functional impact of P-glycoprotein in neuropharmacokinetics]." /><sentence text="P-glycoprotein (P-gp) is a major efflux transporter at the blood-brain barrier (BBB) where it controls the brain distribution of many drugs" /><sentence text=" Clinical translation of preclinical data obtained using invasive methods in animals is difficult due to species differences in P-gp expression and function" /><sentence text=" Positron emission tomography (PET) is an imaging technique allowing for the determination of the tissue kinetics of microdose of radiolabeled compounds" /><sentence text=" Three radiolabeled substrates of the P-gp have been developed for clinical use: [11C]verapamil, [11C]-N-desmethyl-loperamide and [11C]metoclopramide"><entity charOffset="81-95" id="DDI-PubMed.32200996.s5.e0" text="[11C]verapamil" /><entity charOffset="97-125" id="DDI-PubMed.32200996.s5.e1" text="[11C]-N-desmethyl-loperamide" /><entity charOffset="130-149" id="DDI-PubMed.32200996.s5.e2" text="[11C]metoclopramide" /><pair ddi="false" e1="DDI-PubMed.32200996.s5.e0" e2="DDI-PubMed.32200996.s5.e0" /><pair ddi="false" e1="DDI-PubMed.32200996.s5.e0" e2="DDI-PubMed.32200996.s5.e1" /><pair ddi="false" e1="DDI-PubMed.32200996.s5.e0" e2="DDI-PubMed.32200996.s5.e2" /><pair ddi="false" e1="DDI-PubMed.32200996.s5.e1" e2="DDI-PubMed.32200996.s5.e1" /><pair ddi="false" e1="DDI-PubMed.32200996.s5.e1" e2="DDI-PubMed.32200996.s5.e2" /></sentence><sentence text=" These innovative tools enabled the study of P-gp in humans in various patho-physiological conditions including neurological diseases" /><sentence text=" This approach is also useful to predict the risk for drug-drug interaction caused by P-gp inhibitors at the BBB and address its impact for neuropharmacokinetics in vivo in humans" /><sentence text="" /></document>